Overview

A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Status:
Recruiting

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.
UCB Biopharma SRL

Treatments:

Certolizumab Pegol